Cleveland BioLabs to Present at 2015 BIO CEO & Investor Conference
(firmenpresse) - BUFFALO, NY -- (Marketwired) -- 02/05/15 -- (NASDAQ: CBLI) today announced that the Company is scheduled to present at the 2015 BIO CEO & Investor Conference, February 9-10, in New York, NY.
Yakov Kogan, Ph.D., Chief Executive Officer of Cleveland BioLabs, will present the Company''s oncology and biodefense programs on February 10 at 2:00 p.m. ET. A live and archived webcast of the Company''s presentation will be available on the investor page of the Cleveland BioLabs website at .
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company''s lead product candidates are entolimod, which is being developed as radiation countermeasure and a potential cancer treatment, and Curaxin CBL0137, our lead oncology product candidate. The company conducts business in the United States and in the Russian Federation through our three operating subsidiaries, Incuron, LLC, BioLabs 612, LLC and Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, and the Children''s Cancer Institute Australia. To learn more about Cleveland BioLabs, Inc., please visit the Company''s website at .
Contact:
Rachel Levine
Vice President, Investor Relations
Cleveland BioLabs, Inc.
T: (917) 375-2935
E:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 05.02.2015 - 06:30 Uhr
Sprache: Deutsch
News-ID 1335115
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
BUFFALO, NY
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 204 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cleveland BioLabs to Present at 2015 BIO CEO & Investor Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von
Cleveland BioLabs, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
